Conference Report

Multimodality Therapy in Non-Small-Cell Lung Cancer

Source: CCO Independent Conference Coverage of the 2008 Chicago Multidisciplinary Symposium in Thoracic Oncology*

*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.

Multimodality Therapy in Non-Small-Cell Lung Cancer

Program Director: Corey J. Langer, MD, FACP

Faculty:

Jeffrey D. Bradley, MD
Benjamin Movsas, MD

CREDIT INFORMATION

Release Date: 02/13/09

Expiration Date: 02/12/10

Physicians: maximum of 0.75 AMA PRA Category 1 Credits™

Status: Please log in to view status

Learning Objectives

Upon completion of this activity, participants should be able to:

Review the advantages and limitations of stereotactic body radiation therapy for patients with stage I non-small-cell lung cancer
Summarize recent clinical data on the use of targeted therapies in conjunction with chemoradiation and as maintenance treatment following chemoradiation
Discuss new findings on the use of consolidation chemotherapy following concurrent chemoradiation in patients with stage III non-small-cell lung cancer

Topics covered include:

Introduction
Stereotactic Body Radiation Therapy for Stage I NSCLC
Addition of Cetuximab to Chemoradiation in Stage IIIA/B NSCLC
Consolidation Docetaxel Plus Gemcitabine vs Gemcitabine Alone in Stage IIIA/B NSCLC
Gefitinib and V20: Influence on Survival of Patients With NSCLC
IMRT and Proton Therapy for NSCLC
Conclusion

Abstract

Click here to view abstract

Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.